Artykuły w czasopismach na temat „PTC mutations”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „PTC mutations”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Liu, Xiaoli, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K. El-Naggar i Mingzhao Xing. "Highly prevalent TERT promoter mutations in aggressive thyroid cancers". Endocrine-Related Cancer 20, nr 4 (13.06.2013): 603–10. http://dx.doi.org/10.1530/erc-13-0210.
Pełny tekst źródłaRusinek, Dagmara, Aleksandra Pfeifer, Jolanta Krajewska, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, Agnieszka Pawlaczek, Jadwiga Zebracka-Gala i in. "Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients". International Journal of Molecular Sciences 19, nr 9 (6.09.2018): 2647. http://dx.doi.org/10.3390/ijms19092647.
Pełny tekst źródłaClarke, Luka A., Vanessa C. C. Luz, Szymon Targowski, Sofia S. Ramalho, Carlos M. Farinha i Margarida D. Amaral. "Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis". Genes 12, nr 11 (18.11.2021): 1810. http://dx.doi.org/10.3390/genes12111810.
Pełny tekst źródłaGąsior-Perczak, Danuta, Artur Kowalik, Agnieszka Walczyk, Monika Siołek, Krzysztof Gruszczyński, Iwona Pałyga, Estera Mikina i in. "Coexisting Germline CHEK2 and Somatic BRAFV600E Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course". Cancers 11, nr 11 (7.11.2019): 1744. http://dx.doi.org/10.3390/cancers11111744.
Pełny tekst źródłaVidinov, K., R. Dodova, P. Mitev, A. Mitkova, I. Dimitrova, A. Shinkov, R. Ivanova, V. Mitev i R. Kaneva. "Clinicopathological Significance of BRAF (V600E), NRAS (Q61K) and TERT (C228T, C250T and SNP Rs2853669) Mutations in Bulgarian Papillary Thyroid Carcinoma Patients". Acta Medica Bulgarica 48, nr 1 (1.04.2021): 1–8. http://dx.doi.org/10.2478/amb-2021-0001.
Pełny tekst źródłaRusinek, Dagmara, Aleksandra Pfeifer, Marta Cieslicka, Malgorzata Kowalska, Agnieszka Pawlaczek, Jolanta Krajewska, Sylwia Szpak-Ulczok i in. "TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma". Cancers 12, nr 6 (17.06.2020): 1597. http://dx.doi.org/10.3390/cancers12061597.
Pełny tekst źródłaLiu, Jie, Huizheng Li, Rong Du, Nan Fang, Jingbo Zhang, Yu Tang, Jianwei Wang i Qixi Wu. "Targeted next-generation sequencing in papillary thyroid carcinoma of Chinese Han population." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e17574-e17574. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17574.
Pełny tekst źródłaBarzon, Luisa, Giulia Masi, Isabella Merante Boschin, Enrico Lavezzo, Monia Pacenti, Eric Casal Ide, Antonio Toniato, Stefano Toppo, Giorgio Palù i Maria Rosa Pelizzo. "Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma." European Journal of Endocrinology 159, nr 1 (lipiec 2008): 77–80. http://dx.doi.org/10.1530/eje-08-0239.
Pełny tekst źródłaStory, Ellen Shannon, Hsih-Te Yang, Ashley Stewart, Carol J. Farhangfar, Brittany Neelands, Nury Steuerwald, Erin E. Donahue i in. "Genetic alterations in tumor tissue and cell-free DNA in patients with papillary thyroid carcinoma at initial surgery." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): e18083-e18083. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18083.
Pełny tekst źródłaStory, Ellen Shannon, Hsih-Te Yang, Ashley Stewart, Carol J. Farhangfar, Brittany Neelands, Nury Steuerwald, Erin E. Donahue i in. "Genetic alterations in tumor tissue and cell-free DNA in patients with papillary thyroid carcinoma at initial surgery." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): e18083-e18083. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18083.
Pełny tekst źródłaEbina, Aya, Yuki Togashi, Satoko Baba, Yukiko Sato, Seiji Sakata, Masashi Ishikawa, Hiroki Mitani, Kengo Takeuchi i Iwao Sugitani. "TERT Promoter Mutation and Extent of Thyroidectomy in Patients with 1–4 cm Intrathyroidal Papillary Carcinoma". Cancers 12, nr 8 (30.07.2020): 2115. http://dx.doi.org/10.3390/cancers12082115.
Pełny tekst źródłaChoi, Yun-Suk, Seong-Woon Choi i Jin-Wook Yi. "Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution". Journal of Clinical Medicine 10, nr 10 (18.05.2021): 2179. http://dx.doi.org/10.3390/jcm10102179.
Pełny tekst źródłaAl-Kuraya, Khawla Sami, Sarah Siraj, Tariq Masoodi, Abdul Khalid Siraj, Saud Azam, Zeeshan Qadri i Fouad Al-Dayel. "The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas". Journal of the Endocrine Society 5, Supplement_1 (1.05.2021): A871. http://dx.doi.org/10.1210/jendso/bvab048.1779.
Pełny tekst źródłaFang, Yi, Xiao Ma, Jing Zeng, Yanwen Jin, Yong Hu, Jinjing Wang, Ran Liu i Cheng Cao. "The Profile of Genetic Mutations in Papillary Thyroid Cancer Detected by Whole Exome Sequencing". Cellular Physiology and Biochemistry 50, nr 1 (2018): 169–78. http://dx.doi.org/10.1159/000493966.
Pełny tekst źródłaLin, Xiaoqi, Sydney D. Finkelstein, Bing Zhu i Jan F. Silverman. "Molecular analysis of multifocal papillary thyroid carcinoma". Journal of Molecular Endocrinology 41, nr 4 (15.07.2008): 195–203. http://dx.doi.org/10.1677/jme-08-0063.
Pełny tekst źródłaKarunamurthy, Arivarasan, Federica Panebianco, Susan J. Hsiao, Jennie Vorhauer, Marina N. Nikiforova, Simion Chiosea i Yuri E. Nikiforov. "Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules". Endocrine-Related Cancer 23, nr 4 (kwiecień 2016): 295–301. http://dx.doi.org/10.1530/erc-16-0043.
Pełny tekst źródłaHenke, Lauren E., John D. Pfeifer, Thomas J. Baranski, Todd DeWees i Perry W. Grigsby. "Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma". Endocrine Connections 7, nr 12 (grudzień 2018): 1226–35. http://dx.doi.org/10.1530/ec-18-0264.
Pełny tekst źródłaJoshi, Tripti, Ruta Gupta, Luisa Fernanda Olaya A, Bing Yu, Susan McLennan i Elizabeth Lian Chua. "Molecular Genetics in a Cohort of Patients With Concurrent PTC and Melanoma". Journal of the Endocrine Society 5, Supplement_1 (1.05.2021): A1027. http://dx.doi.org/10.1210/jendso/bvab048.2102.
Pełny tekst źródłaGertz, Ryan J., Yuri Nikiforov, William Rehrauer, Lee McDaniel i Ricardo V. Lloyd. "Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population". Archives of Pathology & Laboratory Medicine 140, nr 2 (1.02.2016): 134–39. http://dx.doi.org/10.5858/arpa.2014-0612-oa.
Pełny tekst źródłaHay, Robert, Erin MacRae, Duane Barber, Moosa Khalil i Douglas J. Demetrick. "BRAF Mutations in Melanocytic Lesions and Papillary Thyroid Carcinoma Samples Identified Using Melting Curve Analysis of Polymerase Chain Reaction Products". Archives of Pathology & Laboratory Medicine 131, nr 9 (1.09.2007): 1361–67. http://dx.doi.org/10.5858/2007-131-1361-bmimla.
Pełny tekst źródłade Biase, Dario, Federica Torricelli, Moira Ragazzi, Benedetta Donati, Elisabetta Kuhn, Michela Visani, Giorgia Acquaviva i in. "Not the same thing: metastatic PTCs have a different background than ATCs". Endocrine Connections 7, nr 12 (grudzień 2018): 1370–79. http://dx.doi.org/10.1530/ec-18-0386.
Pełny tekst źródłaGąsior-Perczak, Danuta, Artur Kowalik, Krzysztof Gruszczyński, Agnieszka Walczyk, Monika Siołek, Iwona Pałyga, Sławomir Trepka i in. "Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma". Cancers 13, nr 3 (26.01.2021): 470. http://dx.doi.org/10.3390/cancers13030470.
Pełny tekst źródłaChakraborty, Dhritiman, Sunil Shakya, Sanjana Ballal, Shipra Agarwal i Chandrasekhar Bal. "BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation". Journal of Pediatric Endocrinology and Metabolism 33, nr 11 (26.11.2020): 1465–74. http://dx.doi.org/10.1515/jpem-2020-0174.
Pełny tekst źródłaPekova, Barbora, Sarka Dvorakova, Vlasta Sykorova, Gabriela Vacinova, Eliska Vaclavikova, Jitka Moravcova, Rami Katra i in. "Somatic genetic alterations in a large cohort of pediatric thyroid nodules". Endocrine Connections 8, nr 6 (czerwiec 2019): 796–805. http://dx.doi.org/10.1530/ec-19-0069.
Pełny tekst źródłaSiraj, Sarah, Tariq Masoodi, Abdul K. Siraj, Saud Azam, Zeeshan Qadri, Sandeep K. Parvathareddy, Rong Bu i in. "APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma". Cancers 14, nr 6 (21.03.2022): 1584. http://dx.doi.org/10.3390/cancers14061584.
Pełny tekst źródłaKim, Min Jhi, Jin Kyong Kim, Gi Jeong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Woong Youn Chung, Daham Kim i Kee-Hyun Nam. "TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea". Cancers 14, nr 19 (8.10.2022): 4928. http://dx.doi.org/10.3390/cancers14194928.
Pełny tekst źródłaShen, Xiaopei, Rengyun Liu i Mingzhao Xing. "A six-genotype genetic prognostic model for papillary thyroid cancer". Endocrine-Related Cancer 24, nr 1 (styczeń 2017): 41–52. http://dx.doi.org/10.1530/erc-16-0402.
Pełny tekst źródład’Aquino, Anne E., Tasfia Azim, Nikolay A. Aleksashin, Adam J. Hockenberry, Antje Krüger i Michael C. Jewett. "Mutational characterization and mapping of the 70S ribosome active site". Nucleic Acids Research 48, nr 5 (3.02.2020): 2777–89. http://dx.doi.org/10.1093/nar/gkaa001.
Pełny tekst źródłaLiang, Feng, Haibo Shang, Nikole J. Jordan, Eric Wong, Dayna Mercadante, Josef Saltz, Jerome Mahiou, Hermann J. Bihler i Martin Mense. "High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations". SLAS TECHNOLOGY: Translating Life Sciences Innovation 22, nr 3 (1.02.2017): 315–24. http://dx.doi.org/10.1177/2472630317692561.
Pełny tekst źródłaOwen, Dwight H., Bhavana Konda, Jennifer Sipos, Tom Liu, Amy Webb, Matthew D. Ringel, Cynthia D. Timmers i Manisha H. Shah. "KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer". Journal of the National Comprehensive Cancer Network 17, nr 5 (maj 2019): 409–13. http://dx.doi.org/10.6004/jnccn.2019.7292.
Pełny tekst źródłaJin, Meihua, Dong Eun Song, Jonghwa Ahn, Eyun Song, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim i in. "Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas". Cancers 13, nr 4 (20.02.2021): 892. http://dx.doi.org/10.3390/cancers13040892.
Pełny tekst źródłaWei, Xiaojing, Xiaodong Wang, Jie Xiong, Chen Li, Yixuan Liao, Yongjun Zhu i Jingxin Mao. "Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma". BioMed Research International 2022 (18.05.2022): 1–13. http://dx.doi.org/10.1155/2022/9959649.
Pełny tekst źródłaHan, Jiheun, Young Lyun Oh i Jung-Sun Kim. "Co-Occurrence of Hotspot Point Mutation and Novel Deletion Mutation of TERT Promoter in Solid Variant Papillary Thyroid Carcinoma in a Patient with Synchronous Esophageal Cancer". Diagnostics 11, nr 1 (22.12.2020): 4. http://dx.doi.org/10.3390/diagnostics11010004.
Pełny tekst źródłaPamedytyte, Daina, Vaida Simanaviciene, Dalia Dauksiene, Enrika Leipute, Aurelija Zvirbliene, Valdas Sarauskas, Albertas Dauksa, Rasa Verkauskiene i Birute Zilaitiene. "Association of microRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer". Biomolecules 10, nr 4 (17.04.2020): 625. http://dx.doi.org/10.3390/biom10040625.
Pełny tekst źródłaXing, Mingzhao, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A. Zeiger, Sara Pai i Justin Bishop. "BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence". Journal of Clinical Oncology 32, nr 25 (1.09.2014): 2718–26. http://dx.doi.org/10.1200/jco.2014.55.5094.
Pełny tekst źródłaDegl'Innocenti, Debora, Paola Romeo, Eva Tarantino, Marialuisa Sensi, Giuliana Cassinelli, Veronica Catalano, Cinzia Lanzi i in. "DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells". Endocrine-Related Cancer 20, nr 1 (6.11.2012): 23–37. http://dx.doi.org/10.1530/erc-12-0078.
Pełny tekst źródłaLanda, Iñigo, Ian Ganly, Timothy A. Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A. Ghossein i James A. Fagin. "Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease". Journal of Clinical Endocrinology & Metabolism 98, nr 9 (1.09.2013): E1562—E1566. http://dx.doi.org/10.1210/jc.2013-2383.
Pełny tekst źródłaJohnson, Daniel N., Larissa V. Furtado, Bradley C. Long, Chao Jie Zhen, Michelle Wurst, Ibro Mujacic, Sabah Kadri, Jeremy P. Segal, Tatjana Antic i Nicole A. Cipriani. "Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth". Archives of Pathology & Laboratory Medicine 142, nr 7 (27.03.2018): 838–50. http://dx.doi.org/10.5858/arpa.2017-0118-oa.
Pełny tekst źródłaNam, Myungwoo, Woojung Yang, Ju Young Lee, Jaeyoun Choi, Hansol Choi, Eugene Kim, Emma Yu i in. "753 The immune landscape of papillary thyroid cancer and its association with neoantigen landscape and DNA repair gene mutations". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (listopad 2020): A801. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0753.
Pełny tekst źródłaVuong, Huy Gia, Uyen N. P. Duong, Ahmed M. A. Altibi, Hanh T. T. Ngo, Thong Quang Pham, Hung Minh Tran, Greta Gandolfi i Lewis Hassell. "A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma". Endocrine Connections 6, nr 3 (kwiecień 2017): R8—R17. http://dx.doi.org/10.1530/ec-17-0010.
Pełny tekst źródłaBrown, Ashley E., Khin Sandar Lim, George Corpus, Martha T. Hustek, Tien Anh N. Tran i Chung-Che Chang. "Detection of BRAF mutation in the cytocentrifugation supernatant fluid from fine-needle aspiration of thyroid lesions may enhance the diagnostic yield". CytoJournal 14 (24.02.2017): 4. http://dx.doi.org/10.4103/1742-6413.200935.
Pełny tekst źródłaPlaksa, I. L., M. R. Savchuk, N. V. Shved, N. A. Savelov, D. N. Khmelkova, А. A. Isaev i R. V. Deev. "Mutation profile of the tall cell variant of papillary thyroid carcinoma: analysis of 5 cases using wide-panel next-generation sequencing". Head and Neck Tumors (HNT) 11, nr 1 (24.04.2021): 78–85. http://dx.doi.org/10.17650/2222-1468-2021-11-1-78-85.
Pełny tekst źródłaMuzza, Marina, Gabriele Pogliaghi, Luca Persani, Laura Fugazzola i Carla Colombo. "Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer". Journal of Clinical Medicine 10, nr 12 (16.06.2021): 2645. http://dx.doi.org/10.3390/jcm10122645.
Pełny tekst źródłaSahar, Abd ELmogheth Madani, i Gotsiridze Irine. "Study of BRAF and RAS Mutations in Thyroid Nodules with Indeterminate Cytology and Papillary Thyroid Cancer". Food Processing & Nutritional Science 1, nr 2 (31.12.2020): 105–12. http://dx.doi.org/10.46619/fpns.2020.1-1009.
Pełny tekst źródłaRomei, Cristina, i Rossella Elisei. "A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer". International Journal of Molecular Sciences 22, nr 4 (9.02.2021): 1726. http://dx.doi.org/10.3390/ijms22041726.
Pełny tekst źródłaRusciano, Maria Rosaria, Marcella Salzano, Sara Monaco, Maria Rosaria Sapio, Maddalena Illario, Valentina De Falco, Massimo Santoro i in. "The Ca2+–calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC". Endocrine-Related Cancer 17, nr 1 (marzec 2010): 113–23. http://dx.doi.org/10.1677/erc-09-0214.
Pełny tekst źródłaLupi, Cristiana, Riccardo Giannini, Clara Ugolini, Agnese Proietti, Piero Berti, Michele Minuto, Gabriele Materazzi i in. "Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma". Journal of Clinical Endocrinology & Metabolism 92, nr 11 (1.11.2007): 4085–90. http://dx.doi.org/10.1210/jc.2007-1179.
Pełny tekst źródłaCheng, Shih-Min, Kevin Qu, Adam Abdool, Anthony Sferruzza, Frederic Waldman i Richard E. Reitz. "A molecular diagnostic panel for thyroid cancer disease management." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): 5510. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5510.
Pełny tekst źródłaBaradaran-Heravi, Alireza, Aruna D. Balgi, Sara Hosseini-Farahabadi, Kunho Choi, Cristina Has i Michel Roberge. "Effect of small molecule eRF3 degraders on premature termination codon readthrough". Nucleic Acids Research 49, nr 7 (25.03.2021): 3692–708. http://dx.doi.org/10.1093/nar/gkab194.
Pełny tekst źródłaSong, Young Shin, Seong-Keun Yoo, Hwan Hee Kim, Gyeongseo Jung, Ah-Reum Oh, Ji-Young Cha, Su-jin Kim i in. "Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer". Endocrine-Related Cancer 26, nr 6 (czerwiec 2019): 629–41. http://dx.doi.org/10.1530/erc-17-0562.
Pełny tekst źródła